Four of the world’s largest biopharma’s have agreed to pay around $120 million for exclusive access to genetic data on hundreds of thousands of people. Amgen, AstraZeneca, GlaxoSmithKline, and Johnson & Johnson will each have nine months to pour over the first wave of genomic data coming out of UK Biobank before the global research community gets a chance to look at it. That initial wave will be available at the end of March 2020, and include data from roughly 125,000 participants. The organization noted how the deal terms “mirror” another project it’s working on that sequences exomes in partnership with Regeneron and manufacturers. Learn More